|
05 Sep 2025 |
Granules
|
Consensus Share Price Target
|
512.85 |
573.71 |
- |
11.87 |
buy
|
|
|
|
|
22 Aug 2025
|
Granules
|
Deven Choksey
|
512.85
|
533.00
|
462.00
(11.01%)
|
3.93 |
Buy
|
|
|
We have revised our FY26E/FY27E EPS estimates by -0.6%/-4.6% primarily to reflect a more gradual post-remediation ramp-up at Gagillapur, and a measured margin recovery amid persistent integration and operating costs.
|
|
06 Jun 2025
|
Granules
|
Geojit BNP Paribas
|
512.85
|
599.00
|
529.95
(-3.23%)
|
16.80 |
Accumulate
|
|
|
Validation activities have begun in Phase 2, Genome Valley, in this quarter. Also, the company continues to invest in research and development efforts aimed at building a pipeline of high-value molecules, with a focus on backward integration, especially in the oncology and CNS segment. The company has filed its first oncology molecule in this quarter....
|
|
28 May 2025
|
Granules
|
Motilal Oswal
|
512.85
|
600.00
|
522.40
(-1.83%)
|
16.99 |
Buy
|
|
|
Granules India (GRAN) delivered a slightly better-than-expected revenue in 4QFY25. However, it reported largely in-line EBITDA/PAT for the quarter.
|
|
17 Feb 2025
|
Granules
|
Geojit BNP Paribas
|
512.85
|
580.00
|
522.25
(-1.80%)
|
13.09 |
Accumulate
|
|
|
|
|
25 Jan 2025
|
Granules
|
Motilal Oswal
|
512.85
|
665.00
|
582.00
(-11.88%)
|
29.67 |
Buy
|
|
|
Granules India (GRAN) delivered better-than-expected revenue, while EBITDA/PAT stood in line for the quarter. The traction in finished dosage (FDF) remained robust for six quarters now.
|
|
06 Nov 2024
|
Granules
|
Sharekhan
|
512.85
|
700.00
|
576.45
(-11.03%)
|
36.49 |
Buy
|
|
|
Revenues stood at Rs. 957 crore, falling 19% y-o-y and 18% q-o-q, falling 5% short of our estimates.
|
|
12 Sep 2024
|
Granules
|
Motilal Oswal
|
512.85
|
680.00
|
564.90
(-9.21%)
|
Target met |
Buy
|
|
|
Granules India (GRAN) was issued a Form 483 with six observations for its Gagillapur site after a recent USFDA inspection.
|
|
16 Aug 2024
|
Granules
|
Geojit BNP Paribas
|
512.85
|
732.00
|
662.35
(-22.57%)
|
|
Accumulate
|
|
|
|
|
31 Jul 2024
|
Granules
|
Motilal Oswal
|
512.85
|
680.00
|
630.10
(-18.61%)
|
Target met |
Buy
|
|
|
Granules India (GRAN) posted in-line revenue in 1QFY25. However, it delivered better-than-estimated 1QFY25 EBITDA/PAT led by the increased share of formulation sales.
|
|
31 Jul 2024
|
Granules
|
ICICI Direct
|
512.85
|
765.00
|
630.10
(-18.61%)
|
|
Buy
|
|
|
|
|
26 Jun 2024
|
Granules
|
Sharekhan
|
512.85
|
600.00
|
502.20
(2.12%)
|
Target met |
Buy
|
|
|
We reiterate a Buy on Granules as the company is focusing on value-added products to increase its EBITDA margins to 22% plus from 19% in FY24.
|
|
05 Jun 2024
|
Granules
|
Geojit BNP Paribas
|
512.85
|
470.00
|
440.65
(16.38%)
|
Target met |
Accumulate
|
|
|
|
|
03 Jun 2024
|
Granules
|
ICICI Direct
|
512.85
|
515.00
|
441.10
(16.27%)
|
Target met |
Buy
|
|
|
|
|
23 Mar 2024
|
Granules
|
Sharekhan
|
512.85
|
500.00
|
430.75
(19.06%)
|
Target met |
Buy
|
|
|
|
|
22 Mar 2024
|
Granules
|
ICICI Direct
|
512.85
|
515.00
|
430.75
(19.06%)
|
Target met |
Buy
|
|
|
|
|
01 Dec 2023
|
Granules
|
Geojit BNP Paribas
|
512.85
|
464.00
|
392.85
(30.55%)
|
Target met |
Accumulate
|
|
|
|
|
09 Aug 2023
|
Granules
|
Motilal Oswal
|
512.85
|
370.00
|
322.40
(59.07%)
|
Target met |
Buy
|
|
|
|
|
28 Jul 2023
|
Granules
|
Hem Securities
|
512.85
|
391.00
|
321.30
(59.62%)
|
Target met |
Buy
|
|
|
|
|
19 Jun 2023
|
Granules
|
ICICI Direct
|
512.85
|
360.00
|
294.75
(73.99%)
|
Target met |
Buy
|
|
|
|
|
13 Jun 2023
|
Granules
|
Geojit BNP Paribas
|
512.85
|
342.00
|
285.35
(79.73%)
|
Target met |
Buy
|
|
|
|